Jumpstarting Research: Big Pharma's Out-Licensing Dilemma
Executive Summary
At Windhover's Jumpstart to Products Conference, a number of speakers, including Merck's head of basic research, argued--at least by implication--that Big Pharma needs to do more of the kinds of reformulations and re-indications of existing compounds that net them products faster and with less risk--that allow them to "jumpstart" R&D. For biotechs pursuing a similar strategy, getting starter material--in the form of compounds Pharma has abandoned--is crucial, though few Pharmas are willing to out-license. Lilly is the great exception to this rule: the company's Joe Zakrzewski argues why outlicensing is critical to his firm's success.
You may also be interested in...
Finding a Way Out of Pharma's Dealmaking Dilemma
Big Pharma's being squeezed by deal prices, both for discovery and development assets. And with new capital coming in to fund earlier-stage projects, deals will only get more expensive. But a few forward thinking drug companies are making the seller's market work to their advantage, too, reducing financial exposure and business complexity while upgrading pipelines.
Finding a Way Out of Pharma's Dealmaking Dilemma
Big Pharma's being squeezed by deal prices, both for discovery and development assets. And with new capital coming in to fund earlier-stage projects, deals will only get more expensive. But a few forward thinking drug companies are making the seller's market work to their advantage, too, reducing financial exposure and business complexity while upgrading pipelines.
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Bayer's retreat from the global, primary-care stage into the mid-sized, regionally-focused specialist player arena was forced upon it by its own particular set of challenges. But other drug firms facing similar issues should take note: globalism may not be the best way forward in today's environment.